J Parathyr Dis. 2018;6(2): 87-90.
doi: 10.15171/jpd.2018.27
  Abstract View: 3209
  PDF Download: 4216


Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients

Hamid Reza Omrani 1, Ali Daraizade 2

1 Nephrology and Urology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Internal Medicine, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
*Corresponding Author:


Introduction: Secondary hyperparathyroidism, is a matter of concern in hemodialysis patients that cause renal osteodystrophy eventually.

Objectives: The objective of the study was to compare the efficacy of cholecalciferol with calcitriol for treating secondary hyperparathyroidism.

Materials and Methods: This study is a randomized, controlled study. Around 80 patients with hyperparathyroidism (PTH >300 ρg/mL) and 25(OH)D level <20 ng/mL were divided into two groups to receive cholecalciferol 50 000 IU/3 times in one week or calcitriol 0.25 μg/daily for 12 weeks. Additionally calcium carbonate 1000-1500 mg/d/tablets is prescribed for both groups. Reduction of parathyroid hormone (PTH), changes of plasma albumin-corrected calcium and phosphorus and levels of 25(OH)D were analyzed.

Results: Around 40 patients were randomized into each group. At baseline, plasma albumin-corrected calcium, phosphorus and intact PTH and 25(OH)D had no difference between groups. At week 12, intact PTH levels in cholecalciferol and calcitriol groups were 242.38 ± 16.38 ρg/mL and 237.84 ± 13.65 ρg/mL in respectively. Patients who achieved target intact PTH of <300 ρg/mL were 90% in the cholecalciferol and 95% in the calcitriol group (P = 0.447). Serum calcium and phosphorus were not significantly different in both groups. Serum calcium; 9.07 ± 0.36 mg/dL versus 9.00 ± 0.38 mg/dL (P = 0.607), phosphorus; 4.81 ± 0.55 mg/dL versus 4.15 ± 0.42 mg/dL (P = 0.126) in cholecalciferol and calcitriol groups respectively. Furthermore, serum 25(OH)D levels significantly rise in cholecalciferol group. Serum 25(OH)D levels were 62.98 ±21.03 ng/mL in cholecalciferol group and 18.95 ± 22.70 ng/mL in calcitriol group (P < 0.05).

Conclusion: cholecalciferol can be administered to control secondary hyperparathyroidism and vitamin D(25OH) deficiency in hemodialysis patients. The two drugs are equally efficacious and lead to similar changes in calcium and phosphorus levels.

Please cite this paper as: Omrani HR, Daraizade A. Cholecalciferol versus calcitriol to manage secondary hyperparathyroidism in hemodialysis patients. J Parathyr Dis. 2018;6(2):87-90. doi: 10.15171/jpd.2018.27.

Copyright © 2018 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

First Name
Last Name
Email Address
Security code

Abstract View: 3210

Your browser does not support the canvas element.

PDF Download: 4216

Your browser does not support the canvas element.

ePublished: 04 Jan 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)